Download MendeleyDesign, synthesis, and structure-activity relationships of dihydrofuran-2-one and dihydropyrrol-2-one derivatives as novel benzoxazin-3-one-based mineralocorticoid receptor antagonists.
Hasui, T., Ohra, T., Ohyabu, N., Asano, K., Matsui, H., Mizukami, A., Habuka, N., Sogabe, S., Endo, S., Siedem, C.S., Tang, T.P., Gauthier, C., De Meese, L.A., Boyd, S.A., Fukumoto, S.(2013) Bioorg Med Chem 21: 5983-5994
- PubMed: 23958516 Search on PubMed
- DOI: https://doi.org/10.1016/j.bmc.2013.07.043
- Primary Citation Related Structures:
3WFF, 3WFG - PubMed Abstract:
Dihydrofuran-2-one and dihydropyrrol-2-one derivatives were identified as novel, potent and selective mineralocorticoid receptor (MR) antagonists by the structure-based drug design approach utilizing the crystal structure of MR/compound complex. Introduction of lipophilic substituents directed toward the unfilled spaces of the MR and identification of a new scaffold, dihydropyrrol-2-one ring, led to potent in vitro activity. Among the synthesized compounds, dihydropyrrol-2-one 11i showed an excellent in vitro activity (MR binding IC50=43nM) and high selectivity over closely related steroid receptors such as the androgen receptor (AR), progesterone receptor (PR) and glucocorticoid receptor (GR) (>200-fold for AR and PR, 100-fold for GR).
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-higashi, 2-Chome, Fujisawa, Kanagawa 251-8555, Japan. tomoaki.hasui@takeda.com
Organizational Affiliation:
